Medtronic (NYSE: MDT) has performed very well this year, and with many products coming to market in the next couple of years, it could make for an exciting long-term investment. Medtronic's stock is up 26% year-to-date and is trading near its 52-week high with a market cap of $149 billion.
Let's take a closer look at the medical device company's Q2 fiscal 2020 results that it reported in November, and assess whether the price is right and if the stock is a good buy today -- or if investors should hold off for now.
In November, Medtronic released its second-quarter results. The company beat analyst expectations despite only generating modest sales growth of 3% from the same quarter last year. Its Restorative Therapies Group division has been doing very well for the company, with its sales up 6% in Q2 and revenue from brain therapies growing the most, up by more than 10%.
Source Fool.com